Cargando…

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study

OBJECTIVES: Pembrolizumab plus platinum-based chemotherapy and pembrolizumab monotherapy (PM) both become standard of care in patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) greater than 50%. This study aimed to figure ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ya, Wang, Yanan, Yang, Zhengyu, Hu, Minjuan, Zhang, Yanwei, Qian, Fangfei, Zhang, Wei, Zhang, Bo, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273651/
https://www.ncbi.nlm.nih.gov/pubmed/34262873
http://dx.doi.org/10.3389/fonc.2021.691519
_version_ 1783721412565925888
author Chen, Ya
Wang, Yanan
Yang, Zhengyu
Hu, Minjuan
Zhang, Yanwei
Qian, Fangfei
Zhang, Wei
Zhang, Bo
Han, Baohui
author_facet Chen, Ya
Wang, Yanan
Yang, Zhengyu
Hu, Minjuan
Zhang, Yanwei
Qian, Fangfei
Zhang, Wei
Zhang, Bo
Han, Baohui
author_sort Chen, Ya
collection PubMed
description OBJECTIVES: Pembrolizumab plus platinum-based chemotherapy and pembrolizumab monotherapy (PM) both become standard of care in patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) greater than 50%. This study aimed to figure out the better treatment choice. METHOD: In this retrospective analysis, we compared the clinical efficacy of PM and PC as first-line treatment in NSCLC patients with a PD-L1 ≥50% and negative for genomic alterations in the EGFR and ALK genes. RESULT: Among the population, 115 patients received PC, and 91 patients received PM. Up to Dec 30, 2020, median follow-up was 17.13 months. The median progression-free survival (PFS) rates of PC and PM were 12.37 and 9.60 months (HR: 0.44, p < 0.001), respectively. The median overall survival (OS) rates were NE and 28.91 months (HR: 0.40, p = 0.005), respectively. Subgroup analysis found that the PFS benefit of PC was evident in most subgroups excepting patients with brain metastasis. The 1-year overall survival rates of PC and PM were 89.3% and 76.1%, respectively. The ORR was 61.7 and 46.9% (p = 0.004), respectively. CONCLUSION: In patients with previously untreated, PD-L1 ≥50%, advanced NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard platinum-based chemotherapy seems to be the preferred treatment, which needs to be validated by further prospective trials.
format Online
Article
Text
id pubmed-8273651
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82736512021-07-13 Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study Chen, Ya Wang, Yanan Yang, Zhengyu Hu, Minjuan Zhang, Yanwei Qian, Fangfei Zhang, Wei Zhang, Bo Han, Baohui Front Oncol Oncology OBJECTIVES: Pembrolizumab plus platinum-based chemotherapy and pembrolizumab monotherapy (PM) both become standard of care in patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) greater than 50%. This study aimed to figure out the better treatment choice. METHOD: In this retrospective analysis, we compared the clinical efficacy of PM and PC as first-line treatment in NSCLC patients with a PD-L1 ≥50% and negative for genomic alterations in the EGFR and ALK genes. RESULT: Among the population, 115 patients received PC, and 91 patients received PM. Up to Dec 30, 2020, median follow-up was 17.13 months. The median progression-free survival (PFS) rates of PC and PM were 12.37 and 9.60 months (HR: 0.44, p < 0.001), respectively. The median overall survival (OS) rates were NE and 28.91 months (HR: 0.40, p = 0.005), respectively. Subgroup analysis found that the PFS benefit of PC was evident in most subgroups excepting patients with brain metastasis. The 1-year overall survival rates of PC and PM were 89.3% and 76.1%, respectively. The ORR was 61.7 and 46.9% (p = 0.004), respectively. CONCLUSION: In patients with previously untreated, PD-L1 ≥50%, advanced NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard platinum-based chemotherapy seems to be the preferred treatment, which needs to be validated by further prospective trials. Frontiers Media S.A. 2021-06-28 /pmc/articles/PMC8273651/ /pubmed/34262873 http://dx.doi.org/10.3389/fonc.2021.691519 Text en Copyright © 2021 Chen, Wang, Yang, Hu, Zhang, Qian, Zhang, Zhang and Han https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, Ya
Wang, Yanan
Yang, Zhengyu
Hu, Minjuan
Zhang, Yanwei
Qian, Fangfei
Zhang, Wei
Zhang, Bo
Han, Baohui
Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
title Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
title_full Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
title_fullStr Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
title_full_unstemmed Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
title_short Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
title_sort pembrolizumab alone or combined with chemotherapy in advanced nsclc with pd-l1 ≥50%: results of a retrospective study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273651/
https://www.ncbi.nlm.nih.gov/pubmed/34262873
http://dx.doi.org/10.3389/fonc.2021.691519
work_keys_str_mv AT chenya pembrolizumabaloneorcombinedwithchemotherapyinadvancednsclcwithpdl150resultsofaretrospectivestudy
AT wangyanan pembrolizumabaloneorcombinedwithchemotherapyinadvancednsclcwithpdl150resultsofaretrospectivestudy
AT yangzhengyu pembrolizumabaloneorcombinedwithchemotherapyinadvancednsclcwithpdl150resultsofaretrospectivestudy
AT huminjuan pembrolizumabaloneorcombinedwithchemotherapyinadvancednsclcwithpdl150resultsofaretrospectivestudy
AT zhangyanwei pembrolizumabaloneorcombinedwithchemotherapyinadvancednsclcwithpdl150resultsofaretrospectivestudy
AT qianfangfei pembrolizumabaloneorcombinedwithchemotherapyinadvancednsclcwithpdl150resultsofaretrospectivestudy
AT zhangwei pembrolizumabaloneorcombinedwithchemotherapyinadvancednsclcwithpdl150resultsofaretrospectivestudy
AT zhangbo pembrolizumabaloneorcombinedwithchemotherapyinadvancednsclcwithpdl150resultsofaretrospectivestudy
AT hanbaohui pembrolizumabaloneorcombinedwithchemotherapyinadvancednsclcwithpdl150resultsofaretrospectivestudy